Next-Generation Combination Strategy with Dual-Targeting Antibody and ADC

BioNTech SE has initiated a Phase 1/2 clinical trial (NCT06892548) evaluating the combination of BNT324, a B7-H3-targeting antibody-drug conjugate (ADC), and BNT327, a PD-L1/VEGF-targeting bispecific antibody. This approach goes beyond simple single-target attacks, aiming to simultaneously inhibit tumor immune evasion and angiogenesis while delivering cytotoxic anticancer agents directly to the target. This innovative combination, designed to control the tumor microenvironment, is expected to provide a strong synergistic effect for patients with solid tumors that are resistant to existing immune checkpoint inhibitors. Ultimately, this is a strategic effort to overcome the limitations of single-agent therapies and significantly extend patient survival.

Targeting Unmet Needs in the Difficult-to-Treat Lung Cancer Market

This clinical trial will be conducted in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The global lung cancer therapeutics market is estimated at approximately $33 billion to $36 billion by 2025-2026, with NSCLC accounting for about 85% of this market. However, second-line treatment options for patients who relapse or are refractory to platinum-based chemotherapy or existing immune checkpoint inhibitors are very limited. BioNTech aims to address this significant unmet medical need by focusing on this challenging patient population with advanced lung cancer.

Portfolio Strengthening and Commercialization Roadmap through Mega-Deals

BioNTech has pursued an aggressive business development (BD) strategy to secure key assets for this combination therapy. The bispecific antibody BNT327 was acquired through the acquisition of Biotheus in November 2024 for a total of $950 million, including an upfront payment of $800 million, securing global rights. In June 2025, BioNTech entered into a global co-development agreement with Bristol Myers Squibb (BMS) for a total of $11.1 billion (including a $1.5 billion upfront payment). Furthermore, the B7-H3 ADC, BNT324, is a promising pipeline asset acquired from DualityBio in 2023 for an upfront payment of $170 million. These large investments demonstrate that BioNTech is transforming itself from a COVID-19 vaccine company into a fully-fledged oncology platform company.

Increasingly Competitive Global Landscape and Differentiation

In the global B7-H3 ADC field, Daiichi Sankyo and MSD are currently leading with ifinatamab deruxtecan (I-DXd), which is expected to receive FDA approval in October 2026. GSK's risvutatug rezetecan is also aggressively pursuing the small cell lung cancer market in Phase 3 clinical trials. In the bispecific antibody area, Akeso and Summit Therapeutics' ivonescimab are demonstrating superior efficacy compared to existing standard treatments, shaking up the market. BioNTech aims to differentiate itself from these leading companies through the powerful synergistic combination of its proprietary ADC payload technology and bispecific antibodies.

Design of the Phase 1/2 Trial and Future Prospects

The BNT324-01 clinical trial (NCT06892548) that has just begun will comprehensively evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the combination of the two drugs in patients with advanced lung cancer. In particular, if positive safety data is obtained in Phase 1, which focuses on determining the appropriate dose, objective response rate (ORR) and progression-free survival (mPFS) data can be rapidly generated in Phase 2. The success of this early data will be a critical turning point in determining the value of BioNTech's designed next-generation combination platform. Depending on the clinical results, the company's pipeline value, as well as the global paradigm of anticancer ADC and bispecific antibody combination therapies, may be reshaped.